Currently, the management of T1DM is based on insulin replacement therapy, with little focus on avoiding the onset and progression of the disease, which could be achieved by preventing β-cell damage via the modulation of cytokine response and the production of lipid mediators (Bellenger et al., 2011). The gene discussed is INS; the disease is type 1 diabetes mellitus.